Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$13.69 USD
-0.31 (-2.21%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $13.69 0.00 (0.00%) 6:02 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RCUS 13.69 -0.31(-2.21%)
Will RCUS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RCUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCUS
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
RCUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Is The Options Market Predicting a Spike In Arcus Biosciences (RCUS) Stock?
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
Other News for RCUS
Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update
Here is the next potential market catalyst
Arcus Biosciences Inc (RCUS) Q2 2024 Earnings: Revenue Surpasses Estimates at $39M, GAAP EPS at ...
Arcus Biosciences reports Q2 EPS ($1.02), consensus ($1.10)
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors